Parental Distress and Treatment Adherence in Pediatric Recurrent Medulloblastoma
Parental Distress as a Predictor of Treatment Adherence in Pediatric Recurrent Medulloblastoma: A Prospective Longitudinal Cohort Study
Children with medulloblastoma, an aggressive brain tumor, require prolonged and complex multimodal therapy. Their primary parental caregivers bear the main responsibility for ensuring treatment adherence, yet the psychological toll on these caregivers may undermine their ability to follow prescribed regimens. This study investigates whether multidimensional parental distress predicts overall treatment adherence in this population, and which specific distress domains are most strongly associated with poor adherence.
Parental distress-including depression, anxiety, and posttraumatic stress-is common among parents of children with cancer and may interfere with their ability to manage complex treatment regimens. However, no study has specifically examined whether parental distress predicts treatment adherence in children with recurrent medulloblastoma, a devastating brain tumor with a poor prognosis and no standard treatment protocol.
This prospective longitudinal cohort study aims to investigate whether parental distress is a significant predictor of treatment adherence in children with recurrent medulloblastoma. A total of 450 parent-child dyads will be enrolled across 4 tertiary pediatric oncology centers. Children must have a confirmed diagnosis of recurrent medulloblastoma and be receiving active treatment. Parents (primary caregivers) will complete validated questionnaires at baseline assessing depression, anxiety, stress, and trauma-related distress using the DASS-21 and IES-R. Treatment adherence will be monitored over a 12-month follow-up period using electronic medication monitoring caps, clinic attendance records, and parent-reported medication logs.
The primary outcome is the proportion of prescribed chemotherapy doses taken (treatment adherence rate). Secondary outcomes include trajectories of adherence over time and the relationship between specific dimensions of parental distress (depression, anxiety, stress, posttraumatic stress) and adherence patterns. The study will also examine whether child clinical factors (e.g., molecular subgroup, prior treatment history) and family demographic factors moderate this relationship.
Findings from this study may inform the development of targeted psychosocial interventions to support distressed parents and improve treatment adherence-and ultimately clinical outcomes-in this vulnerable pediatric population. Participants can expect to be enrolled in the study for approximately 12 months.
Studieoversikt
Status
Intervensjon / Behandling
Studietype
Registrering (Antatt)
Kontakter og plasseringer
Studiekontakt
- Navn: Zhigang Lan, M.D. PhD.
- Telefonnummer: 18980606446
- E-post: 158075478@qq.com
Studiesteder
-
-
Sichuan
-
Chengdu, Sichuan, Kina
- Rekruttering
- West China Hospital of Sichuan University
-
Ta kontakt med:
- Zhigang Lan, M.D. PhD.
- Telefonnummer: 18980606446
- E-post: 158075478@qq.com
-
Ta kontakt med:
- E-post: 158075478@qq.com
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
- Barn
- Voksen
Tar imot friske frivillige
Prøvetakingsmetode
Studiepopulasjon
Beskrivelse
Inclusion Criteria(Children):
- Diagnosis of medulloblastoma with documented recurrence (radiographic or histopathological confirmation)
- Age ≤ 18 years at enrollment
- Currently receiving active treatment for recurrent disease
- Life expectancy ≥ 3 months
Inclusion Criteria (Parents/Caregivers):
- Primary caregiver responsible for medication administration and treatment coordination
- Age ≥ 18 years
- Able to read and understand study materials in [English]
- Willing to complete study assessments
Exclusion Criteria:
- Child receiving exclusively palliative/hospice care
- Parent with severe psychiatric illness or cognitive impairment preventing informed consent or questionnaire completion
- Child enrolled in another interventional trial that would confound adherence measurement
Studieplan
Hvordan er studiet utformet?
Designdetaljer
Kohorter og intervensjoner
Gruppe / Kohort |
Intervensjon / Behandling |
|---|---|
|
Parent-Child Dyads with Recurrent Medulloblastoma
Children with recurrent medulloblastoma receiving active treatment and their primary caregivers
|
Ikke relevant - observasjonsstudie
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Overall Treatment Adherence Score
Tidsramme: 12 months from enrollment
|
Composite adherence score (range 0-10) based on the 8-item Morisky Medication Adherence Scale (MMAS-8) plus clinic attendance and home-care behavior index.
Higher scores indicate better adherence.
|
12 months from enrollment
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Parenting Stress Index-Short Form (PSI-SF) Total Score
Tidsramme: 12 months from enrollment
|
36-item scale assessing parental distress across three subdomains: Parental Distress, Parent-Child Dysfunctional Interaction, and Difficult Child.
Range 36-180, higher scores indicate greater stress.
|
12 months from enrollment
|
|
DASS-21 Subscale Scores
Tidsramme: 12 months from enrollment
|
Depression, Anxiety and Stress Scale-21 scores for each subscale (range 0-21), with higher scores indicating greater symptom severity.
|
12 months from enrollment
|
Samarbeidspartnere og etterforskere
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Antatt)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- WestChinaH-HX-2026-002
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
IPD-planbeskrivelse
IPD-deling Støtteinformasjonstype
- STUDY_PROTOCOL
- SEVJE
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .
Kliniske studier på Medulloblastom
-
Sabine Mueller, MD, PhDHar ikke rekruttert ennåMedulloblastom | Medulloblastom, barndom | Medulloblastom TilbakevendendeForente stater
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)FullførtTilbakevendende medulloblastom i barndommen | Tilbakevendende ependymom | Tilbakevendende medulloblastomForente stater
-
University of California, San FranciscoWashington University School of Medicine; University of Washington; St. Baldrick... og andre samarbeidspartnereRekrutteringEpendymom | Medulloblastom | Medulloblastom, barndom | Medulloblastom Tilbakevendende | Ependymom i hjernen | Ependymom ondartetForente stater
-
University of FloridaPediatric Neuro-Oncology ConsortiumRekrutteringTilbakevendende medulloblastomForente stater
-
National Cancer Institute (NCI)FullførtTilbakevendende medulloblastom i barndommenForente stater
-
Pediatric Brain Tumor ConsortiumNational Cancer Institute (NCI); St. Jude Children's Research Hospital; Senhwa...AvsluttetMedulloblastom | Medulloblastom, barndom | Medulloblastom TilbakevendendeForente stater
-
National Cancer Institute (NCI)FullførtTilbakevendende medulloblastom i barndommenForente stater
-
University of FloridaChildren's National Research InstituteRekrutteringResidiverende gruppe 3 medulloblastom | Residiverende gruppe 4 (Non-SHH/Non-WNT) MedulloblastomForente stater
-
Sabine Mueller, MD, PhDMayo Clinic; Vyriad, Inc.; No More Kids With Cancer; The Matthew Larson Foundation...FullførtMedulloblastom Tilbakevendende | Atypisk teratoide/rhabdoide svulst | Medulloblastom, barndom, tilbakevendendeForente stater
-
Gustave Roussy, Cancer Campus, Grand ParisAvsluttetHøyrisiko medulloblastomFrankrike
Kliniske studier på Ikke relevant - observasjonsstudie
-
University of Michigan Rogel Cancer CenterNational Cancer Institute (NCI)RekrutteringProstata karsinomForente stater
-
Mayo ClinicRekrutteringOndartet fast neoplasma | Neoplasma i hematopoetisk og lymfatisk systemForente stater
-
Ohio State University Comprehensive Cancer CenterLilly FoundationRekrutteringAnatomisk stadium IV brystkreft AJCC v8 | Avansert brystkarsinom | Metastatisk brystkarsinomForente stater
-
Mayo ClinicNational Cancer Institute (NCI)Påmelding etter invitasjonBarrett Esophagus | Esophageal adenokarsinomForente stater
-
University of Southern CaliforniaNational Cancer Institute (NCI); Merck Sharp & Dohme LLCRekrutteringOndartet fast neoplasma | Neoplasma i hematopoetisk og lymfatisk systemForente stater
-
Roswell Park Cancer InstituteRekrutteringSigarettrøykerelatert karsinomForente stater
-
Children's Oncology GroupHar ikke rekruttert ennåHematopoietisk og lymfatisk neoplasma i barndommen | Malignt solid neoplasma i barndommen
-
Ohio State University Comprehensive Cancer CenterAmerican Association for Cancer ResearchRekrutteringAnatomisk stadium I brystkreft AJCC v8 | Anatomisk stadium II brystkreft AJCC v8 | Anatomisk stadium III brystkreft AJCC v8 | Brystkarsinom | Hormonreseptorpositivt brystkarsinomForente stater
-
University of Southern CaliforniaNational Cancer Institute (NCI)RekrutteringOndartet fast neoplasma | Neoplasma i hematopoetisk og lymfatisk systemForente stater
-
University of Southern CaliforniaNational Cancer Institute (NCI)RekrutteringEndometriekarsinomForente stater